Screener
Immunome IMNM Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 21,878 | 41,651 |
| Total current liabilities | 27,412 | 44,990 |
| Operating lease liabilities, net of current portion | 3,694 | 3,855 |
| Total liabilities | 31,106 | 48,845 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2026 and December 31, 2025; 113,171,396 and 113,133,199 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 11 | 11 |
| Additional paid-in capital | 1,370,678 | 1,362,496 |
Item 1. Financial Statements.
FAQ
- What is Immunome's total liabilities?
- Immunome (IMNM) reported total liabilities of $31.11M in Q1 2026.
- How has Immunome's total liabilities changed year-over-year?
- Immunome's total liabilities decreased by 12.5% year-over-year, from $35.57M to $31.11M.
- What is the long-term trend for Immunome's total liabilities?
- Over 5 years (2020 to 2025), Immunome's total liabilities has grown at a 72.7% compound annual growth rate (CAGR), from $3.18M to $48.85M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Immunome's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude